NuGene International, Inc. Reinforces Medical Proficiency

IRVINE, Calif., March 10, 2015 /PRNewswire/ -- NuGene International, Inc. ("NuGene") (OTCQB: NUGN), the maker of age-defying aesthetic products for skin and hair rejuvenation, has added two recognized doctors to its advisory board, further expanding its knowledge base in dermatology and microsurgery.

Dr. Vivian Bucay, of San Antonio, Texas, has been featured as a skin expert in several publications, including Allure, Cosmetic Surgery Times, Elle, More, Shape, Prevention, and Good Housekeeping. She has been featured as a keynote speaker across the globe on a wide scope of topics ranging from innovations in facial aesthetics to neuromodulators to cancer survival.

Dr. Bucay is certified by the American Board of Dermatology and serves as a Clinical Assistant Professor in the Department of Physician Assistant Studies of the UT Health Science Center San Antonio. She is recognized nationally for her expertise in minimally invasive facial rejuvenation through the combined use of neuromodulators, injectable dermal fillers, and skin resurfacing. Considered to be one of the pre-eminent dermatologists in the country, Dr. Bucay's credentials span a wide scope of biomedical research, patient care, and medical education.

"I was very happy to be selected to NuGene's advisory board," stated Dr. Bucay. "I have a strong interest in skin rejuvenation and recovery after my personal battle with stage 4 melanoma, and I am passionate about my philosophy that beautiful skin starts with healthy skin."

Also added to the board is Dr. Mark Kobayashi, who specializes in aesthetic surgery that includes all areas of plastic surgery including reconstructive and microvascular surgery. His microsurgical expertise is used to recreate a breast following cancer with free tissue transfer. He is a widely published author of medical journal articles and is Associate Clinical Professor of Surgery at the Aesthetic & Plastic Surgery Institute of the University of California, Irvine.

"As a science-based cosmeceutical company, we are extremely focused on building our knowledge base in all areas relating to our current and anticipated product lines," said NuGene CEO Ali Kharazmi when announcing the selections. "We have an excellent team of advisors and these two individuals represent the caliber and talent of the people we look to for advice and industry knowledge."

About NuGene International, Inc.

NuGene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media.  The US Department of Health and Human Services calls regenerative medicine the "next evolution of medical treatments".  The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report.  NuGene's cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue.  NuGene's exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations.  The company has two patents pending covering 15 unique applications and inventions.  NuGene's goal is to leverage its extensive knowledge and expertise to develop age defying regenerative cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.

Forward-Looking Statements

This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by NuGene International may not proceed as contemplated, and by all other matters and assumptions specified in NuGene's filings with the Securities and Exchange Commission, especially those risks and other matters described under "Risk Factors" within NuGene's Form 8-K filed with the Commission on January 6, 2015. These statements are made based upon current expectations that are subject to risk and uncertainty. NuGene does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information.

Investor/ Media Relations:
Chris Rosgen
Capital Market Relations
(949) 481-9739

Logo - http://photos.prnewswire.com/prnh/20150305/179797LOGO

SOURCE NuGene International, Inc.

Related Links

http://www.nugene.com